Skip to main content

Genetic tests

Jul 2024

Updates in the Spanish Common Package of Benefits

On June 19, 2024, the Order SND/606/2024, of June 13, came into force. This Order, among other things, amends Annexes I, II, III, VI, and VII of Royal Decree 1030/2006, of September 15, which establishes the Common Package of Benefits of the National Health System and the procedure for its update. The changes mostly concern in-vitro diagnostics, ENT, pulmonary and airways, cardiovascular, and some other fields.
Apr 2024

Med Tech-related technology assessments and clinical guidelines from NICE in March 2024

In March 2024, the National Institute for Health and Care Excellence (NICE) published two new Health Technology Evaluations using early value assessment (digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people, and digital technologies for managing non-specific low back pain). Furthermore, three new clinical guidelines were published, four clinical guidelines, and two Health Technology Evaluations were updated.
Feb 2024

New national catalog for genetic tests released in Spain

On January 23, 2024, the Ministry of Health introduced a new national catalog, which guarantees the Spanish population's genetic tests nationwide. Currently, the catalog includes 672 tests in eight disease areas, including adult and pediatric oncohematology, pharmacogenomics, hereditary metabolic and mitochondrial diseases, and others. Twelve more disease areas are expected to be added in 2024.
Sep 2023

New version of the CCAM Nomenclature published in France

At early September 2023, the new version of the classification of procedure codes (CCAM v.73) was published. Several changes were introduced, including the creation of two permanent codes, one provisionally registered code, and three new grouping codes for 280 dental procedures.
Sep 2023

Launch of the national newborn screening for spinal muscular atrophy in Sweden

On August 30, 2023, the National Board of Health and Welfare introduced national screening for spinal muscular atrophy (SMA) in newborns. The screening test will identify children with homozygous deletion in the SMN1 gene and 1–3 copies of the SMN2 gene. As a result, those affected by the most severe forms of SMA can receive treatment before the onset of symptoms.
Jul 2023

Extended reimbursement for next-generation sequencing (NGS) in Belgium

In late June 2023, the National Institute for Health and Disability Insurance (INAMI-RIZIV) decided to extend reimbursement for molecular biology tests by next-generation sequencing (NGS) for one year until June 30, 2024. NGS in oncology and hemato-oncology are temporarily reimbursed as a pilot under a specific agreement (Convention) with INAMI-RIZIV from 2019.